Takeda S, Kida H, Takazakura E, Yokoyama H, Kobayashi K
Department of Internal Medicine, Kurobe City Hospital, Japan.
Nihon Jinzo Gakkai Shi. 1997 Jul;39(5):490-6.
In a attempt to clarify the effects of methylprednisolone pulse therapy on the insidious (subacute) type of crescentic glomerulonephritis with slow, but steady deterioration of renal function and poor response to treatment, we analyzed the clinical course of 24 patients (male:female = 15:9) with a mean age of 48.5 years. They fulfilled the following criteria: 1) crescents were observed in more than 50% of the glomeruli, 2) the increment of serum creatinine (Cr) could be determined sequentially on three or more occasions before treatment, and reciprocals of serum Cr declined with slopes of less than 1.0 x 10(-2) dl/mg/day, 3) corticosteroids and/or immunosuppressants were administered. The patients were divided into two groups: pulse therapy group (P) (15 patients), to which methylprednisolone 500 or 1,000 mg a day was administered intravenously for three consecutive days, and a conventional therapy group (C) (9 patients). There were no differences between groups P and C in clinical parameters, including sex, age, underlying diseases, urinary protein, blood pressure, serum Cr and slope of 1/Cr before treatment, and pathological findings, including percentages of glomeruli with crescents and degree of interstitial lesions. However, improvement of serum Cr, which was defined as a decline to the normal range or less than half of the pretreatment level, was observed in 9 (60%) in group P vs. only 1 (11%) in group C (p < 0.05). Re-biopsies were performed after treatment in 6 patients of group P with an improvement of serum Cr, and showed a decrease in the rate of crescent formation and almost complete loss of cellular crescents. At 1, 2 and 3 years follow-up, the renal survival rates were 86, 70 and 53%, respectively, in group P vs. 67, 14 and 14% respectively, in group C (p < 0.05). No serious side effects were observed in group P. These results suggest that methylprednisolone pulse therapy may be very effective for the insidious type of crescentic glomerulonephritis.
为了阐明甲泼尼龙冲击疗法对隐匿性(亚急性)新月体性肾小球肾炎的影响,这类肾炎肾功能缓慢但持续恶化且治疗反应不佳,我们分析了24例患者(男∶女 = 15∶9)的临床病程,他们的平均年龄为48.5岁。他们符合以下标准:1)超过50%的肾小球中观察到新月体;2)治疗前可在三次或更多次连续测定血清肌酐(Cr),且血清Cr的倒数下降斜率小于1.0×10⁻² dl/mg/天;3)已给予皮质类固醇和/或免疫抑制剂。患者分为两组:冲击疗法组(P组)(15例患者),静脉连续三天给予甲泼尼龙500或1000 mg/天,以及传统疗法组(C组)(9例患者)。P组和C组在临床参数方面无差异,包括性别、年龄、基础疾病、尿蛋白、血压、治疗前血清Cr及1/Cr斜率,以及病理表现,包括有新月体的肾小球百分比和间质病变程度。然而,血清Cr改善(定义为降至正常范围或低于治疗前水平的一半)在P组有9例(60%),而C组仅1例(11%)(p < 0.05)。P组血清Cr改善的6例患者治疗后进行了重复肾活检,结果显示新月体形成率降低且细胞性新月体几乎完全消失。在1年、2年和3年随访时,P组的肾脏存活率分别为86%、70%和53%,而C组分别为67%、14%和14%(p < 0.05)。P组未观察到严重副作用。这些结果表明甲泼尼龙冲击疗法可能对隐匿性新月体性肾小球肾炎非常有效。